The FDA has approved pembrolizumab for the treatment of certain surgically removable tumors before and after resection. The U.S. Food and Drug Administration (FDA) has approved the immunotherapy pembrolizumab (Keytruda) for use in combination...
The FDA approved nivolumab for some patients with melanoma whose tumor was completely removed through surgery and has not spread. The U.S. Food and Drug Administration (FDA) has approved the checkpoint inhibitor nivolumab (Opdivo)...
Rising prevalence of non-melanoma skin cancer leads to more deaths across the globe and other highlights from this week in cancer news, selected by the editors of Cancer Today.
AACR is a pioneer in the study of racial/ethnic and other disparities in cancer research and care. The 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically...
The FDA approved encorafenib with binimetinib as a treatment for certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration has approved encorafenib (Braftovi) with binimetinib (Mektovi) to treat adult patients...
Minority groups less likely to receive palliative care, and radiation oncology meeting focuses on shorter radiation courses.
Centuries ago, when several Native tribes in northeastern America were at constant war, a peacemaker came to stop the violence. The peacemaker held up a single arrow and snapped it in front of tribal...
In the beginning of his cancer journey, Edward Cutler felt unlucky. In 2012, he saw an ad suggesting that men his age who had previously smoked should be screened for an abdominal aortic aneurysm....
As the temperatures start to drop and the leaves begin to change color, enjoy the latest selection of studies hand-picked by the editors of the 10 AACR journals. These include reports on a novel...
Intravenous delivery of antibodies may lower the risk of severe infections by 90% in patients with multiple myeloma, a recent study found. The risk of serious infection among patients receiving a new type of...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More